Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors

Journal of Cancer Survivorship

Volumn 2, Issue 3, 2008, Pages 128-137

  Haugnes, H S ^a   Aass, N ^b   Fossa S D ^b,c   Dahl, O ^d,e   Klepp, O ^f   Wist, E A ^g   Wilsgaard, T ^a   Bremnes, R M ^a,h  

^a UNIVERSITY OF TROMSØ   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cardiovascular; Cisplatin; Morbidity; Mortality; SCORE; Testicular cancer

Indexed keywords

EID: 52249116769     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-008-0054-1     Document Type: Article

References (46)

1. Bray F, Dahl T, van Dijk T, et al. Cancer in Norway 2006. Available at www.kreftregisteret.no/forekomst_og_overlevelse_2006/CIN2006_web.pdf (2007).
2. S Krege J Beyer R Souchon P Albers W Albrecht F Algaba 2008 European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I Eur Urol 53 478 496
3. JA Gietema DT Sleijfer PH Willemse KH Schraffordt E van Ittersum WM Verschuren 1992 Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer Ann Intern Med 116 709 715
4. D Strumberg S Brugge MW Korn S Koeppen J Ranft G Scheiber 2002 Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer Ann Oncol 13 229 236
5. H Sagstuen N Aass SD Fosså O Dahl O Klepp EA Wist 2005 Blood pressure and body mass index in long-term survivors of testicular cancer J Clin Oncol 23 4980 4990
6. M Boyer D Raghavan PJ Harris J Lietch A Bleasel JC Walsh 1990 Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer J Clin Oncol 8 21 26
7. HS Haugnes N Aass SD Fossa O Dahl O Klepp EA Wist 2007 Components of the metabolic syndrome in long-term survivors of testicular cancer Ann Oncol 18 241 248
8. T Wethal J Kjekshus J Røislien T Ueland AK Andreassen R Wergeland 2007 Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer Journal of Cancer Survivorship 1 8 16
9. MT Meinardi JA Gietema WT van der Graaf DJ van Veldhuisen MA Runne WJ Sluiter 2000 Cardiovascular morbidity in long-term survivors of metastatic testicular cancer J Clin Oncol 18 1725 1732
10. RA Huddart A Norman M Shahidi A Horwich D Coward J Nicholls 2003 Cardiovascular disease as a long-term complication of treatment for testicular cancer J Clin Oncol 21 1513 1523
11. A van den Belt-Dusebout J Nuver R de Wit JA Gietema WW Bokkel Huinink PTR Rodrigus 2006 Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 24 467 475
12. GK Zagars MT Ballo AK Lee SS Strom 2004 Mortality after cure of testicular seminoma J Clin Oncol 22 640 647
13. GS Lederman TA Sheldon JT Chaffey TS Herman RS Gelman CN Coleman 1987 Cardiac disease after mediastinal irradiation for seminoma Cancer 60 772 776
14. GE Hanks T Peters J Owen 1992 Seminoma of the testis: long-term beneficial and deleterious results of radiation Int J Radiat Oncol Biol Phys 24 913 919
15. SD Fossa E Gilbert GM Dores J Chen KA [tmp] McGlynn S Schonfeld 2007 Noncancer causes of death in survivors of testicular cancer J Natl Cancer Inst 99 533 544
16. G De Backer E Ambrosioni K Borch-Johnsen C Brotons R Cifkova J Dallongeville 2003 European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in clinical practice Eur Heart J 24 1601 1610
17. I Graham D Atar K Borch-Johnsen G Boysen G Burell R Cifkova 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 Suppl 2 E1 40
18. RM Conroy K Pyorala AP Fitzgerald S Sans A Menotti G De Backer 2003 Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 987 1003
19. M Brydoy SD Fossa O Klepp RM Bremnes EA Wist T Wentzel-Larsen 2005 Paternity following treatment for testicular cancer J Natl Cancer Inst 97 1580 1588
20. I Hartz I Njolstad AE Eggen 2005 Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromso Study 2001 Eur Heart J 26 2673 2680
21. O Klepp O Dahl P Flodgren U Stierner AM Olsson J Oldbring 1997 Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer Eur J Cancer 33 1038 1044
22. N Aass O Klepp E Cavallin-Stahl O Dahl H Wicklund B Unsgaard 1991 Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience J Clin Oncol 9 818 826
23. O Klepp AM Olsson H Henrikson N Aass O Dahl AE Stenwig 1990 Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian testicular cancer group J Clin Oncol 8 509 518
24. SD Fossa JP Droz G Stoter SB Kaye K Vermeylen R Sylvester 1995 Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group Br J Cancer 71 619 624
25. MH Cullen SP Stenning MC Parkinson SD Fossa SB Kaye AH Horwich 1996 Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a medical research council report J Clin Oncol 14 1106 1113
26. A Horwich RT Oliver PM Wilkinson GM Mead SJ Harland MH Cullen 2000 A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party Br J Cancer 83 1623 1629
27. A Horwich DT Sleijfer SD Fossa SB Kaye RT Oliver MH Cullen 1997 Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional medical research council/European organization for research and treatment of cancer trial J Clin Oncol 15 1844 1852
28. SD Fossa A Horwich JM Russell JT Roberts MH Cullen NJ Hodson 1999 Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. Medical Research Council Testicular Tumor Working Group J Clin Oncol 17 1146
29. MJ Peckham TJ [tmp] McElwain A Barrett WF Hendry 1979 Combined management of malignant teratoma of the testis Lancet 2 267 270
30. L Getz JA Sigurdsson I Hetlevik AL Kirkengen S Romundstad J Holmen 2005 Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study BMJ 331 551 556
31. KM Anderson PM Odell PW Wilson WB Kannel 1991 Cardiovascular disease risk profiles Am Heart J 121 293 298
32. KM Anderson PW Wilson PM Odell WB Kannel 1991 An updated coronary risk profile. A statement for health professionals Circulation 83 356 362
33. P Brindle J Emberson F Lampe M Walker P Whincup T Fahey 2003 Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study BMJ 327 1267
34. HW Hense H Schulte H Lowel G Assmann U Keil 2003 Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts Eur Heart J 24 937 945
35. HW Hense 2004 Observations, predictions and decisions-assessing cardiovascular risk assessment Int J Epidemiol 33 235 239
36. HB Hubert M Feinleib PM [tmp] McNamara WP Castelli 1983 Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study Circulation 67 968 977
37. H Tunstall-Pedoe K Kuulasmaa M Mahonen H Tolonen E Ruokokoski 1999 Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations The Lancet 353 1547 1557
38. A Ergin P Muntner R Sherwin J He 2004 Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Am J Med 117 219 227
39. C Nord T Bjoro D Ellingsen A Mykletun O Dahl O Klepp 2003 Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer Eur Urol 44 322 328
40. J Svartberg D von Muhlen H Schirmer E Barrett-Connor J Sundfjord R Jorde 2004 Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study Eur J Endocrinol 150 65 71
41. J Svartberg M Midtby KH Bonaa J Sundsfjord RM Joakimsen R Jorde 2003 The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study Eur J Endocrinol 149 145 152
42. DE Laaksonen L Niskanen K Punnonen K Nyyssonen TP Tuomainen VP Valkonen 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men Diabetes Care 27 1036 1041
43. KT Khaw M Dowsett E Folkerd S Bingham N Wareham R Luben 2007 Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study Circulation 116 2694 2701
44. GA Laughlin E Barrett-Connor J Bergstrom 2008 Low serum testosterone and mortality in older men J Clin Endocrinol Metab 93 68 75
45. J Nuver AJ Smit BH Wolffenbuttel WJ Sluiter HJ Hoekstra DT Sleijfer 2005 The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer J Clin Oncol 23 3718 3725
46. J Nuver AJ Smit DT Sleijfer AI van Gessel AM van Roon MJ van der 2004 Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer Eur J Cancer 40 701 706